论文部分内容阅读
目的:探讨血浆转化生长因子-β1和纤溶酶原激活物抑制因子-1与2型糖尿病患者合并冠心病的相关性。方法:100例2型糖尿病患者根据是否合并冠心病分为糖尿病组(56例),合并冠心病组(44例)。应用双抗体夹心ELISA法检测其血浆转化生长因子-β1和纤溶酶原激活物抑制因子-1含量,同时以40例健康者作为对照组。结果:2型糖尿病各组血浆转化生长因子-β1和纤溶酶原激活物抑制因子-1含量均较对照组显著升高(P<0.05);合并冠心病组血浆转化生长因子-β1和纤溶酶原激活物抑制因子-1含量较单纯糖尿病组显著升高(P<0.05)。2型糖尿病患者血浆转化生长因子-β1与纤溶酶原激活物抑制因子-1呈正相关。结论:2型糖尿病患者血浆转化生长因子-β1和纤溶酶原激活物抑制因子-1的继发性改变在糖尿病动脉粥样硬化发生发展中起重要作用。
Objective: To investigate the correlation between plasma transforming growth factor-β1 and plasminogen activator inhibitor-1 in patients with type 2 diabetes mellitus complicated with coronary heart disease. Methods: One hundred patients with type 2 diabetes were divided into diabetic group (56 cases) and coronary heart disease group (44 cases) according to their coronary heart disease. Serum levels of TGF-β1 and plasminogen activator inhibitor-1 were measured by double-antibody sandwich ELISA. Forty healthy controls were used as control group. Results: The levels of TGF-β1 and PAI-1 in type 2 diabetes mellitus group were significantly higher than those in control group (P <0.05). The levels of plasma transforming growth factor-β1 and fibronectin Compared with simple diabetic group, the content of TKI-1 was significantly increased (P <0.05). There was a positive correlation between plasma transforming growth factor-β1 and plasminogen activator inhibitor-1 in type 2 diabetic patients. Conclusion: The secondary changes of plasma transforming growth factor-β1 and plasminogen activator inhibitor-1 in type 2 diabetic patients play an important role in the development of atherosclerosis in diabetic patients.